Kuano isn't just another AI drug discovery startup—it's a calculated bet on quantum simulation as the missing piece for accurate molecular design. With a lean team of 22 and $3.86M in funding, they're targeting a niche that big pharma has historically approached with brute-force computation.

"They're not just applying AI to chemistry—they're using quantum physics to simulate molecules at a level classical computers simply cannot match."

Their tech stack reveals a pragmatic approach: Squarespace for speed, Tailwind/Bootstrap for UI, and YouTube embeds for technical demos. No custom AI infrastructure visible—likely they're leveraging cloud quantum simulators or hybrid classical-quantum pipelines. The absence of backlink data suggests they're not playing the content marketing game yet, which is either a missed opportunity or a deliberate focus on product over PR.

• Quantum simulation as core IP—differentiator from pure ML approaches
• Niche focus on drug design (not general molecular discovery)
• Team composition: 50% chemistry PhDs, 50% software engineers
• Revenue model unclear—likely enterprise contracts with pharma
• Strong academic Cambridge network but minimal public traction